TLX Telix Pharmaceuticals Ltd

Nasdaq telixpharma.com


$ 8.88 $ -0.13 (-1.44 %)    

Thursday, 20-Nov-2025 12:11:24 EST
QQQ $ 592.18 $ -19.49 (-3.19 %)
DIA $ 459.17 $ -7.51 (-1.61 %)
SPY $ 657.59 $ -15.31 (-2.28 %)
TLT $ 89.34 $ 0.35 (0.39 %)
GLD $ 372.89 $ -2.30 (-0.61 %)
$ 9.04
$ 9.10
$ 8.88 x 130
$ 8.90 x 126
$ 8.88 - $ 9.10
$ 8.93 - $ 30.36
61,899
na
3.03B
$ 1.95
$ 98.01
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces results from the ZIRCON-X study which fin...

 telix-pharmaceuticals-enters-q4-on-strong-footing-with-stabilized-pricing-pressures-upgraded-annual-sales-guidance

Telix Pharmaceuticals posts 53% Q3 revenue growth to $206 million, lifts FY25 guidance to up to $820 million amid strong PSMA i...

Core News & Articles

Telix Pharmaceuticals (NASDAQ:TLX) sees Q3 sales of $206.000 million.

Core News & Articles

Telix Pharmaceuticals (NASDAQ:TLX) raises FY2025 sales outlook from $770.000 million-$800.000 million to $800.000 million-$820....

Core News & Articles

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that the United States (U.S.) Centers for...

Core News & Articles

Citigroup analyst Laura Sutcliffe initiates coverage on Telix Pharmaceuticals (NASDAQ:TLX) with a Buy rating and announces P...

Core News & Articles

HC Wainwright & Co. analyst Robert Burns maintains Telix Pharmaceuticals (NASDAQ:TLX) with a Buy and lowers the price ta...

Core News & Articles

JP Morgan downgrades Telix Pharmaceuticals (NASDAQ:TLX) from Overweight to Neutral.

 telix-gets-second-fda-rejection-for-kidney-cancer-drug

FDA sent a second CRL to Telix, delaying its kidney cancer PET drug. Analysts weigh pricing pressure, and growth opportunities.

Core News & Articles

Wedbush analyst David Nierengarten reiterates Telix Pharmaceuticals (NASDAQ:TLX) with a Outperform and maintains $22 price t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION